TPSD1

Across TCGA pan-cancer cohorts, TPSD1 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of TPSD1’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where TPSD1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types TPSD1 is over-expressed in tumor, although a few such as CCRCC and PDAC show the opposite, repressed pattern.

HNSC, LUAD, and LSCC are the cancer types where TPSD1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TPSD1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	III,IV	+0.460	<.001	11	view →
LUAD	Female	III,IV	+0.707	<.001	9	view →
LSCC	Female	All	+0.610	<.001	9	view →
COAD	Female	II,III,IV	+0.486	<.001	9	view →
CCRCC	Male	All	−0.400	<.001	7	view →
PDAC	Male	All	−0.254	.011	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

TPSD1–HNSC

Open the HNSC breakdown →